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.00) # 50-3.80*; 50-3.02 (3.94-3.80, 3.80-3.69, 3.69-3.58-3.49, 3.49-3.40, 3.40-3.32, 3.32-3.25, 3.25-3.19, 3.19-3.13, 3.13-3.07, 3.07-3 .02) # R sym or R merge 8.4* (30.9*); 9.9 (31. 1, 35.4, 35.1, 39.8, 57.9, 73.2, 88.9, 82.6, 88.2) 19.8* (52.5*); 20.3 (49.4, 54.4, 50.6, 48.6, 52.8, 49.8, 63.8, 60.2, 87.5, 131.8, 153.6 The wild-type and mutant HIV-1 HXBc2 envelope glycoproteins are listed, with the numbering of the envelope glycoprotein amino acid residues corresponding to that of the HIV-1 HXBc2 envelope glycoproteins, as per current convention (Korber et al., 1998 ; https://www.hiv.lanl.gov/content/sequence/HIV/REVIEWS/H XB2.html). The mutations result in the substitution of the amino acid residue shown on the right for the amino acid residue shown on the left of the number. The number of times independent experiments were performed is indicated by n. Relative infectivity was determined by infecting Cf2Th-CD4/CXCR4 cells with 10,000 RT units of wild-type and mutant viruses expressing luciferase. The luciferase activity in the target cells infected with each mutant virus was divided by that in the cells infected with the wild-type virus to obtain the relative infectivity. In parallel experiments, infections were performed in the presence of increasing concentrations of BMS-378806. The BMS-378806 concentrations that inhibited 50% of the mutant virus infection (IC 50 ) are indicated. ND is not determined. Supplementary Figure 6 . Flow cytometric analysis of the effect of BMS-378806 on sCD4 binding and sCD4-induced conformational changes of the HIV-1 JR-FLΔCT Env expressed on the cell surface. Structural rearrangements were measured using C34-Ig, which binds the gp41 HR1 region, and sCD4 binding was detected by a FITC-conjugated anti-CD4 antibody. APC, allophycocyanin; FITC, fluorescein isothiocyanate. 
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